drugset / Trial / NCT00905021
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The investigators want to find out if the treatments used in this study are helpful to patients that are diagnosed with hormone receptor positive metastatic breast cancer. The investigators want to also look at any side effects that could happen while patients are on the study treatments. The investigators want to see if there are any changes that could show us if your cancer is responding to the study treatments.
Timeline
- Start
- 2010-03
- Primary completion
- 2011-01
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |